百奥泰公告，公司于2024年10月8日召开公司第二届董事会第十八次会议，审议通过了《关于就 BAT2206签署授权许可及生产、供货和商业化协议的议案》。根据协议约定，百奥泰于近日收到由吉瑞 医药一次性支付的250万美元里程碑付款。该笔款项的到账，进一步充盈了公司的现金储备，也为公司 后续管线研发和国际化战略的推进提供助力。截至本公告披露日，BAT2206注射液已获美国食品药品监 督管理局和欧洲药品管理局批准上市，美国注册商品名为STARJEMZA®，欧洲注册商品名为 Usymro®；已向国家药品监督管理局提交上市申请，目前正在评审中。 ...

截至本公告披露日，BAT2206（乌司奴单抗）注射液已获美国食品药品监督管理局（FDA）和欧洲药品 管理局（EMA）批准上市，美国注册商品名为STARJEMZA®，欧洲注册商品名为 Usymro® ； 已向国 家药品监督管理局（NMPA）提交上市申请，目前正在评审中。 格隆汇1月9日丨百奥泰(688177.SH)公布，根据协议约定，百奥泰于近日收到由 Hikma 支付的1,000 万美 元里程碑付款（实际到账金额须扣除银行手续费）。该笔款项的到账，进一步充盈了公司的现金储备， 也为公司后续管线研发和国际化战略的推进提供助力。 ...

Core Viewpoint - Baotai Biopharmaceutical Co., Ltd. has received approval from the European Commission for Usymro®, a biosimilar drug for treating moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe active Crohn's disease in adults and children, marking a significant milestone for the company [2][3] Company Overview - Baotai is a global biopharmaceutical company based in Guangzhou, China, focused on developing innovative drugs and biosimilars for various diseases, including cancer and autoimmune disorders [2][3] - The company has successfully launched multiple drugs, including Adalimumab and Tocilizumab, in various markets, establishing itself as a leader in antibody drug development [3] Recent Developments - The approval of Usymro® follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2025, highlighting the company's commitment to advancing its biosimilar pipeline [2] - In October 2024, Baotai signed a licensing and commercialization agreement with Gilead Sciences for BAT2206, another biosimilar, covering markets in the EU, UK, Switzerland, and other regions [2]